Kiora Pharmaceuticals
KPRX
6 hedge funds and large institutions have $1.04M invested in Kiora Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
24% less capital invested
Capital invested by funds: $1.37M → $1.04M (-$335K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$236K |
| 2 |
IA
IFP Advisors
Tampa,
Florida
|
+$32.1K |
| 3 |
SSG
Summit Securities Group
New York
|
+$21.4K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$140K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $834K | +$236K | +22 | +31% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $130K | +$21.4K | +2 | +17% |
|
|
IA
3
IFP Advisors
Tampa,
Florida
| $24K | +$32.1K | +3 | New |
|
|
BFA
4
BlackRock Fund Advisors
San Francisco,
California
| $18K | – | – | – |
|
|
SSG
5
Summit Securities Group
New York
| $17K | +$21.4K | +2 | New |
|
|
VIA
6
Vantage Investment Advisors
State College,
Pennsylvania
| $11K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
8
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
|
BIM
9
BlackRock Investment Management
Wilmington,
Delaware
| $1K | – | – | – |
|
10
Morgan Stanley
New York
| $1K | – | – | – |
|
|
11
Millennium Management
New York
| – | -$140K | -10 | Closed |
|
|
12
UBS Group
Zurich,
Switzerland
| – | -$8K | -1 | Closed |
|
|
AIM
13
Acrospire Investment Management
Chicago,
Illinois
| – | -$5K | – | – |
|
KPRX Hedge Fund Activity: Q3 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2016, worth a combined $1.04M — down 24% from $1.37M a quarter earlier.
Fund positioning in KPRX was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 0 trimmed.
The largest buyer was Sabby Management, adding an estimated $236K. The largest seller was Millennium Management, exiting entirely with an estimated $140K sold.
- 6 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $1.04M of Kiora Pharmaceuticals stock for Q3 2016, down 24% quarter-over-quarter.
- 2 funds opened new Kiora Pharmaceuticals positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Kiora Pharmaceuticals buyer in Q3 2016 was Sabby Management, an estimated $236K added.
- The largest Kiora Pharmaceuticals seller in Q3 2016 was Millennium Management, an estimated $140K sold.
Based on aggregated 13F filings for Q3 2016.